Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function



Status:Recruiting
Conditions:Hematology, Metabolic
Therapuetic Areas:Hematology, Pharmacology / Toxicology
Healthy:No
Age Range:18 - 60
Updated:3/30/2019
Start Date:June 2016
End Date:June 2019
Contact:Raul Chertkoff, MD
Email:raul@protalix.com
Phone:+972-4-9028100

Use our guide to learn which trials are right for you!

A Randomized, Double Blind, Active Control Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function in Patients With Fabry Disease Previously Treated With Agalsidase Beta

This is a randomized, double blind, active control study of PRX-102 (pegunigalsidase alfa) in
Fabry disease patients with impaired renal function. Patients treated for approximately 1
year with agalsidase beta and on a stable dose for at least 6 months will be screened and
then randomized to continue treatment with 1mg/kg agalsidase beta or to treatment with 1
mg/kg of PRX-102. The identity of the enzyme will be blinded to the patient and the
investigator. Patients will receive intravenous infusions every two weeks. Patients will be
randomized in a 2:1 ratio of PRX-102 to agalsidase beta. Randomization will be stratified by
urinary protein to creatinine ratio (UPCR) of < or ≥ 1 g/g by spot urine sample. No more than
50% of the patients will be female.


Inclusion Criteria:

- Symptomatic adult Fabry disease patients, age 18-60 years

1. Males: Plasma and/or leucocyte alpha galactosidase activity (by activity assay)
less than 30% mean normal levels and one or more of the characteristic features
of Fabry disease

i. neuropathic pain

ii. cornea verticillata

iii. clustered angiokeratoma

2. Females:

a. historical genetic test results consistent with Fabry pathogenic mutation and
one or more of the described characteristic features of Fabry disease:

i. neuropathic pain

ii. cornea verticillata

iii. clustered angiokeratoma

b. or in the case of novel mutations a first degree male family member with Fabry
disease with the same mutation, and one or more of the characteristic features of
Fabry disease

i. neuropathic pain

ii. cornea verticillata

iii. clustered angiokeratoma

- Screening eGFR by CKD-EPI equation 40 to 120 mL/min/1.73 m²

- Linear negative slope of eGFR based on at least 3 serum creatinine values over
approximately 1 year (range of 9 to 18 months, including the value obtained at the
screening visit) of ≥ 2 mL/min/1.73 m²/year

- Treatment with a dose of 1 mg/kg agalsidase beta per infusion every 2 weeks for at
least one year and at least 80% of 13 (10.4) mg/kg total dose over the last 6 months.

- Female patients and male patients whose co-partners are of child-bearing potential
agree to use a medically accepted method of contraception, not including the rhythm
method.

Exclusion Criteria:

- History of anaphylaxis or Type 1 hypersensitivity reaction to agalsidase beta

- Known non-pathogenic Fabry mutations

- History of renal dialysis or transplantation

- History of acute kidney injury in the 12 months prior to screening, including specific
kidney diseases (e.g., acute interstitial nephritis, acute glomerular and vasculitic
renal diseases); non-specific conditions (e.g, ischemia, toxic injury); as well as
extrarenal pathology (e.g., prerenal azotemia, and acute postrenal obstructive
nephropathy)

- Angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB)
therapy initiated or dose changed in the 4 weeks prior to screening

- Patient with a screening eGFR value between 91-120 mL/min/1.73 m², having an
historical eGFR value higher than 120 mL/min/1.73 m² (during 9 to 18 months before
screening)

- Urine protein to creatinine ratio (UPCR) > 0.5 g/g and not treated with an ACE
inhibitor or ARB

- Cardiovascular event (myocardial infarction, unstable angina) in the 6 month period
before randomization

- Congestive heart failure NYHA Class IV

- Cerebrovascular event (stroke, transient ischemic attack) in the 6 month period before
randomization

- Known history of hypersensitivity to Gadolinium contrast agent that is not managed by
the use of pre-medication

- Female subjects who are pregnant, planning to become pregnant during the study, or are
breastfeeding

- Presence of any medical, emotional, behavioral or psychological condition that, in the
judgment of the Investigator and/or Medical Director, would interfere with the
patient's compliance with the requirements of the study
We found this trial at
25
sites
1919 E Thomas Rd
Phoenix, Arizona 85006
(602) 933-1000
Principal Investigator: Kristin E. Lindstrom, MD
Phone: 602-933-4363
Phoenix Children's Hospital Phoenix Children's Hospital has provided hope, healing, and the best healthcare for...
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
1648 Pierce Dr NE
Atlanta, Georgia 30322
(404) 727-5640
Principal Investigator: William Wilcox, MD
Phone: 404-727-5624
Emory University School of Medicine Emory University School of Medicine has 2,359 full- and part-time...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
Principal Investigator: Amel Karaa
Phone: 617-726-1561
?
mi
from
Boston, MA
Click here to add this to my saved trials
3333 Burnet Avenue # Mlc3008
Cincinnati, Ohio 45229
 1-513-636-4200 
Principal Investigator: Robert Hopkin, MD
Phone: 513-636-4760
Cincinnati Children's Hospital Medical Center Patients and families from across the region and around the...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Los Angeles, California 90095
310-825-4321
Principal Investigator: Anjay Rastogi, MD
Phone: 310-954-2692
University of California at Los Angeles The University of California, Los Angeles (UCLA) is an...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
920 Madison Ave
Memphis, Tennessee 38163
Principal Investigator: John L. Jefferies, MD
Phone: 901-448-5750
?
mi
from
Memphis, TN
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
503 494-8311
Principal Investigator: Amy C. Yang, MD
Phone: 503-418-2385
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
?
mi
from
Portland, OR
Click here to add this to my saved trials
1876 5th Avenue South
Birmingham, Alabama 35233
Principal Investigator: Eric L Wallace, MD
Phone: 205-975-9676
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
225 E Chicago Ave
Chicago, Illinois 60611
(312) 227-4000
Principal Investigator: Joel Charrow, MD
Phone: 773-880-4462
Ann & Robert H. Lurie Children's Hospital of Chicago Ann & Robert H. Lurie Children
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Dallas, Texas 75226
Principal Investigator: Raphael Schiffmann, MD, MHSc
Phone: 214-820-4533
?
mi
from
Dallas, TX
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
919-684-8111
Principal Investigator: Marie McDonald
Phone: 919-681-1982
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
?
mi
from
Durham, NC
Click here to add this to my saved trials
Fairfax, Virginia 22031
Principal Investigator: Ozlem Goker-Alpan, MD
Phone: 571-308-1900
?
mi
from
Fairfax, VA
Click here to add this to my saved trials
Gainesville, Florida 32608
Principal Investigator: Maegawa Gustavo, MD, PhD
Phone: 352-294-5559
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
Grand Rapids, Michigan 49525
Principal Investigator: Kahn Nedd, MD
Phone: 616-954-0600
?
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Iowa City, Iowa 52242
Principal Investigator: Myrl Holida, PA
Phone: 319-356-2007
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
1 Children's Way
Little Rock, Arkansas 72202
(501) 364-1100
Principal Investigator: Thomas Burrow, MD
Phone: 501-364-2966
Arkansas Children's Hospital Arkansas Children's Hospital (ACH) is the only pediatric medical center in Arkansas...
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
8701 W Watertown Plank Rd
Milwaukee, Wisconsin
(414) 955-8296
Principal Investigator: William Rhead
Phone: 414-266-3345
Medical College of Wisconsin The Medical College (MCW) of Wisconsin is a major national research...
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Minneapolis, Minnesota 55455
Principal Investigator: Chester Whitley
Phone: 612-625-7422
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Morgantown, West Virginia 26506
(304) 293-0111
Principal Investigator: Tarachandra Narumanchi, MD
Phone: 304-293-7332
West Virginia University West Virginia University, founded in 1867, has a long and rich history...
?
mi
from
Morgantown, WV
Click here to add this to my saved trials
New York, New York 10021
Principal Investigator: Heather Lau, MD
Phone: 212-263-8344
?
mi
from
New York, NY
Click here to add this to my saved trials
101 The City Drive South
Orange, California 92868
Principal Investigator: Virginia Kimonis
Phone: 714-456-5791
?
mi
from
Orange, CA
Click here to add this to my saved trials
1115 Avenida de Mayo
Pergamino, Buenos Aires
Principal Investigator: Norberto R Antongiovanni, MD
Phone: +54 2477433928
?
mi
from
Pergamino,
Click here to add this to my saved trials
3414 Fifth Avenue
Pittsburgh, Pennsylvania 15213
Principal Investigator: Gerard Vockley, Md, PhD
Phone: 412-692-7746
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Salt Lake City, Utah 84113
Principal Investigator: Nicola Longo, MD, PhD
Phone: 801-587-3605
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
San Diego, California 92093
Principal Investigator: Bruce Barshop
Phone: 619-543-5237
?
mi
from
San Diego, CA
Click here to add this to my saved trials